Can I read PARP Inhibitors in Ovarian Cancer Trials on EtoBox?

PARP Inhibitors in Ovarian Cancer Trials by Vito Damasco is a document available to read on EtoBox.

What is PARP Inhibitors in Ovarian Cancer Trials about?

PARP inhibitors show promise for treating cancers with defective DNA repair pathways like BRCA mutations. In clinical trials, the PARP inhibitor olaparib demonstrated a 46% response rate in BRCA-mutated ovarian cancer with a median response duration of 8 months and was well tolerated. Further studies are exploring olaparib as a maintenance therapy and in combination with chemotherapy. Biomarkers are needed to identify which sporadic ovarian cancers may also benefit from PARP inhibition due to "BRCAness".

Author

Vito Damasco

Language

EN